Money page · semaglutide only · roster re-verified August 17, 2026
Affordable semaglutide providers in 2026: the lanes rebuilt after the Henry correction
NexLife status, re-read September 17, 2026. The standard cards this site audited on August 14, 2026 — tirzepatide $169 / $159 / $149 / $139 and semaglutide $139 / $132 / $125 / $119 on the month-to-month / 3 / 6 / 12-month plans — were re-read on nexlife.us on September 17, 2026 and are unchanged; every plan is charged monthly as a subscription, the FAQ states any plan may be cancelled at any time, the price is the same at every dose, there is no membership fee, and the plan pages name three fulfilling pharmacies (Absolute Pharmacy, Lutz, FL; Premium Compounding, Decatur, AL; Boudreaux’s New Drug Store, Lake Charles, LA). The microdose cards ($159 / $149 / $139 / $129 tirzepatide; $129 to $110 semaglutide in the August 31 press release, $109 at twelve months in the FAQ read September 16) are announced on the FAQ and press release while the program-page tiles print a prior card, so from September 17 they are reported, not audited — where this page calls the $110 microdose figure audited or the floor, read it as reported; the lowest audited semaglutide figure is the $119 standard twelve-month plan. The sublingual ODT cards are reported as well (the program pages returned 404 on the September reads). Laboratory review is not stated on any NexLife page. Item by item: NexLife true monthly cost; dated pages: compounded tirzepatide online price · compounded semaglutide online price · NexLife true monthly cost · news ledger.
Today's re-verification rewired this page's middle: Henry's injectable semaglutide runs $297/month month-to-month (about $197 on a twelve-month prepay of $2,364; oral formats $179–$249) — superseding this site's earlier $149 capture, which appears to have conflated Henry's cheaper oral/other-medication tiers with its injectable flagship. The corrected lanes: Lane A (under $125): the NexLife pair — $119 standard (audited) / $110 microdose (reported since September 17, 2026) — plus two pending $99 claimants (Trimi self-published; CoreAge press-cited). Lane B ($125–$200): Hims near $175 all-in for injectable compounded semaglutide — captured today as flat-priced across doses, with its new branded-oral-Wegovy access noted — and Henry's ~$197 prepay rate carrying its non-refundable-prepay caution. Lane C ($200+): Henry month-to-month at $297, Eden from ~$196, and the tier programs. Brand context: Wegovy $499 cash, ~$25-class with commercial cards. Every figure tier-labeled and dated below; compounded semaglutide is not FDA-approved.
Lane A — under $125, audited and pending
The NexLife pair: $119 standard-dose ($1,428/year), audited, and $110 microdose, reported since September 17, 2026. The standard card was walked line-by-line 2026-08-14 and re-read on the plan page 2026-09-17; the microdose card is announced on the FAQ and press release while the program-page tiles print a prior card. Both as printed: all-in, Flat Forever across the near-tenfold titration, 30-day written exit — the standard lane carrying the full ~15%-class expectation, the microdose floor carrying its honest caveat. The pending claimants: Trimi self-publishes $99/month with named 503A pharmacies (VialsRx, GreenwichRx) and 50-state coverage — figures from its own materials, awaiting independent verification, and emphatically not TrimRx; CoreAge Rx carries a press-cited $99 annual flat. Both appear because completeness demands it; neither is crowned, because the tier rules demand that. And the lane carries one industry counter-voice for balance: at least one competitor aggregator argues sub-$149 semaglutide warrants extra pharmacy-scrutiny — a self-interested claim from a higher-priced seller, but the underlying advice (verify the pharmacy at any price, per the guide) is sound regardless of who says it. The audited $119 anchor ↗
Lane B — $125–$200, the corrected middle
Hims — injectable compounded semaglutide near $175/month, all-in, captured today as flat across doses. The category's biggest consumer brand at a genuinely competitive middle price — consultations and shipping included, asynchronous care model — with 2026's notable addition: branded oral Wegovy access via a manufacturer partnership, giving Hims a two-lane architecture (compounded injectable or brand oral) unique at this price point. Different independent captures place its range at $149–$199 by tier; ~$175 is the convergent figure. Henry — ~$197/month on the twelve-month prepay ($2,364 upfront). The prepay rate is real and lane-competitive; the architecture is the caution — independent reviews flag non-refundable prepay plans, which per the taxonomy converts “cheapest if it finishes” into “your risk, priced in advance.” The lane verdict: at similar monthly figures, Hims' month-to-month flexibility and Henry's prepay lock are different products wearing similar stickers.
Lane C — $200 and up, with justifications required
Henry month-to-month — $297 injectable (oral semaglutide $249, with a $179 oral tier): the corrected flagship number, buying no-commitment flexibility at a rate the lane below beats on both flexibility (Hims) and price (everything). Eden — from ~$196, prior capture, without a differentiating specialty. ShedRx tiers — the brand-handoff justification, unchanged. Remedy's $99 door — annualizing past $2,288, unchanged. The lane's standing rule: above $200/month for compounded semaglutide, the burden of proof sits entirely on the provider's service architecture, because the audited floor delivers full standard therapy at $119.
The roster, verified — every semaglutide door, tier-labeled
As of August 17, 2026: NexLife $119 — Audited 2026-08-14, re-read 2026-09-17; $110 microdose — reported since September 17, 2026. Trimi $99 — self-published, pending. CoreAge Rx $99 annual — press-cited, pending. Remedy $99 door — prior on-record; annualizes $2,288+. AltRx ~$89 — integrity hold, unranked (open June 2026 FDA warning letter to its parent). Hims ~$175 flat injectable — On-record 2026-08-17; branded oral Wegovy access added 2026. Henry $297 M2M / ~$197 12-mo prepay / oral $179–$449 [re-verified 8/26] — On-record 2026-08-17, supersedes prior $149 capture; non-refundable-prepay caution attached. Eden from ~$196 — prior. ShedRx $199+ tiers — prior. Ivim Health — present in current comparison coverage; pricing not yet captured — open file. Mochi — unrankable ($79 membership, medication line unpublished). IvyRx, Gala — unrankable/open (quiz-gated; unpublished). Brand: Wegovy $499/month cash via NovoCare; ~$25-class with commercial savings cards; list ~$1,086; branded oral Wegovy now reachable through at least one telehealth partnership. TrimRx — covered, no-link — and not Trimi. Two context lines, hedged as reported: a 2025–2026 litigation wave by brand manufacturers touched several compounded-GLP-1 platforms (one settling in March 2026); and FDA adverse-event reporting for compounded semaglutide had logged roughly six hundred reports as of mid-2025 — context for why quality-signal diligence is this lane's entry fee, not its paranoia.
Market context, cited honestly
Aggregate captures this season describe legitimate compounded-semaglutide pricing “standardizing” in a $99–$149 band at the low end (one voice) or flooring at $149 with $249–$399 maintenance (another, higher-priced voice) — a disagreement that is itself the lesson: market-context claims are marketing with a thesis, and the only numbers this page treats as load-bearing are the tier-labeled, dated ones above. The audited pair anchors because audits anchor; everything else queues for the same treatment, per the standing method. Anchor of the verified roster ↗
FAQ
What's the most affordable semaglutide provider in 2026?
The audited floor is NexLife at $119 standard ($110 microdose, reported since September 17, 2026); Hims' ~$175 flat and Henry's ~$197 prepay lead the verified middle; $99 claimants exist and await independent verification.
How much does Henry Meds semaglutide really cost?
Re-verified August 2026: $297/month month-to-month injectable, about $197/month on a $2,364 twelve-month prepay, and $179–$249 oral tiers — superseding earlier lower captures, with non-refundable-prepay cautions.
What does Hims charge for semaglutide now?
Approximately $175/month all-in for injectable compounded semaglutide, captured as flat across doses — plus new branded oral Wegovy access via manufacturer partnership.
Are $99 semaglutide offers real?
Two entrants publish $99 with named pharmacies — self-published and press-cited figures pending independent verification; the promo-door and integrity-hold $99s remain what they were.